ElectroCore, Inc. is a bioelectronic medicine and general wellness company specializing in non-invasive vagus nerve stimulation (nVNS) technology platforms. Its primary product, gammaCore, is a prescription-only handheld device designed for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for hemicrania continua and paroxysmal hemicrania. The company also offers Truvaga 350 and Truvaga Plus, consumer electronics general wellness products for personal use, with the latter featuring app-enabled functionality. Additionally, ElectroCore provides TAC-STIM for human performance enhancement and gammaCore Sapphire, a portable, reusable, rechargeable prescription device for various primary headache conditions. It has expanded its portfolio through the acquisition of NeuroMetrix, incorporating the Quell platform to address chronic pain and wellness markets. Operating in the United States, United Kingdom, and internationally, ElectroCore focuses on neurology, pain management, and wellness sectors, delivering drug-free therapies via innovative neuromodulation devices. Founded in 2005 and headquartered in Rockaway, New Jersey, the company plays a key role in advancing non-invasive bioelectronic treatments.